https://www.reatapharma.com/investors/news/news-details/2023/Reata-Pharmaceuticals-Announces-FDA-Approval-of-SKYCLARYS-Omavaloxolone-the-First-and-Only-Drug-Indicated-for-Patients-with-Friedreichs-Ataxia/default.aspx
FDA SKYCLARYS
Apri International Ataxia Research Conference 2015
Apri Poster presentation
Epigenetic Therapy for Friedreich Ataxia ( HDACì) James Rusche ecc.
